| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Outline of Final Research Achievements |
Macro TSH was found in 0.5% of patients with subclinical hypothyroidism. The size of macro TSH was >150kDa compared with 28kDa of monomeric TSH. Macro TSH was mostly a complex of TSH with IgG and the bioactivity was found low by the experiment using FRTL5. Three commercially available TSH assay systems (Elecsys, Centaur, Architect) all recognized macro TSH. It was recommended to screen macro TSH before initiating thyroid hormone replacement therapy. Non-IgG type macroprolactin was found to cross-react to Architect assay system that reportedly seldom recognized macroprolactin. Insulin glargine and aspart were found to be more antigenic and be prone to produce anti-insulin antibody in patients with diabetes on insulin therapy.
These antibodies should be examined to understand the pathophysiology and to provide better treatments for many patients.
|
